A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Non-Proliferative Diabetic Retinopathy
Research Goals
To evaluate the efficacy and safety of intravitreal OTX–TKI (0.45 mg axitinib implant) in participants with NPDR.
